A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

NCT03255096 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma
High-Grade B-cell Lymphoma

Interventions

DRUG: RO6870810
DRUG: Venetoclax
DRUG: Rituximab

Sponsor

Hoffmann-La Roche